Pact to Facilitate Merck's Work on Biosimilars

February 2011
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p89
Trade Publication
The article reports on the alliance between Merck & Co. Inc. and Parexel International Corp. in which Parexel provides access to global clinical development services for designated biosimilar candidates to Merck BioVentures, a division of Merck focusing on the delivery of biosimilars in the U.S.


Related Articles

  • Merck, PAREXEL in Biosimilars Pact.  // Contract Pharma;Jan/Feb2011, Vol. 13 Issue 1, p28 

    The article offers news briefs related to the pharmaceutical industry in the U.S. Merck & Co. Inc. and Parexel International Corp. formed an alliance in which Parexel will allow access to global clinical development services for designated biosimilar candidates to Merck BioVentures. PPD Inc....

  • Smoothing the E-submission process.  // R&D Magazine;Nov2002, Vol. 44 Issue 11, p44 

    Reports on the collaboration between PAREXEL International Corp. and Datafarm Inc. in November 2002, in their efforts to make electronic regulatory submission processes efficient. Types of services that will be marketed by PAREXEL; Details of the agreement.

  • Merck, Pfizer announce collaboration on drug. Zanki, To // njbiz;5/6/2013, p2 

    This article reports on a partnership between pharmaceutical firms Merck & Co. Inc. and Pfizer Inc. to develop and market the latter's experimental Type 2 diabetes drug, Ertugliflozin.

  • Merck Partnering Strong Under New Management.  // BioWorld Today;3/2/2012, Vol. 23 Issue 42, p6 

    The article reports on the strong partnering activity of Merck and Co. Inc. under the leadership of new chief executive officer (CEO) Ken Franzier as evidenced by the 50 licensing and partnership deals completed by the company in 2011.

  • Clarification.  // BioWorld Today;2/13/2013, Vol. 24 Issue 30, p2 

    A correction to the article regarding the goal of Merck and Co. Inc. and Lycera Corp.'s collaboration that was published in the February 12, 2013 issue is presented.

  • Merck, Greenpharma collaborate on cosmetic active ingredient.  // BioSpectrum;Aug2013, Vol. 11 Issue 8, p14 

    The article reports on the collaboration between pharmaceutical companies Merck & Co. Inc. and Greenpharma S.A.S. to market the active cosmetic ingredient of the extract of poppy seeds in India.

  • Riboswitching: BioRelix Inks Antibacterial Merck Deal.  // Bioworld Week;10/11/2010, Vol. 18 Issue 41, p2 

    The article focuses on the partnership deal between BioRelix Inc. and Merck & Co. Inc.

  • Merck Backs Out of Two Galapagos Partnerships.  // Bioworld Week;2/14/2011, Vol. 19 Issue 7, p3 

    The article reports on the move of Merck & Co. Inc. to withdraw its partnership with Galapagos NV.

  • Delivering knowledge where it's needed .  // Australian Nursing Journal;Dec2001/Jan2002, Vol. 9 Issue 6, p19 

    Deals with the partnership formed by the International Council for Nurses (ICN) with Merck and Co. Inc. and medical publisher Harcourt of the United States. Objectives of the partnership program; Views of ICN on the education of nurses.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics